Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit.

Kripke DF.

F1000Res. 2016 May 19;5:918. doi: 10.12688/f1000research.8729.1. eCollection 2016. Review.

2.

Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population-based study.

Johnson CF, Frei C, Downes N, McTaggart SA, Akram G.

Br J Gen Pract. 2016 Jun;66(647):e410-5. doi: 10.3399/bjgp16X685213. Epub 2016 Apr 25.

3.

Challenges and Enablers of Deprescribing: A General Practitioner Perspective.

Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM.

PLoS One. 2016 Apr 19;11(4):e0151066. doi: 10.1371/journal.pone.0151066. eCollection 2016.

4.

Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.

Bach P, Walton G, Hayashi K, Milloy MJ, Dong H, Kerr T, Montaner J, Wood E.

Am J Public Health. 2016 Jun;106(6):1067-72. doi: 10.2105/AJPH.2016.303090. Epub 2016 Mar 17.

5.
6.

Hypovitaminosis D and Other Risk Factors of Femoral Neck Fracture in South Indian Postmenopausal Women: A Pilot Study.

Paul TV, Selvan SA, Asha HS, Thomas N, Venkatesh K, Oommen AT, Mathai T, Seshadri M.

J Clin Diagn Res. 2015 Jun;9(6):OC19-22. doi: 10.7860/JCDR/2015/9444.6131. Epub 2015 Jun 1.

7.

Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines.

Requena G, Logie J, Martin E, Boudiaf N, González González R, Huerta C, Alvarez A, Webb D, Bate A, García Rodríguez LA, Reynolds R, Schlienger R, Gardarsdottir H, de Groot M, Klungel OH, de Abajo F, Douglas IJ.

Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:79-87. doi: 10.1002/pds.3822. Epub 2015 Jun 26.

9.

Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep.

Swanson CM, Shea SA, Stone KL, Cauley JA, Rosen CJ, Redline S, Karsenty G, Orwoll ES.

J Bone Miner Res. 2015 Feb;30(2):199-211. doi: 10.1002/jbmr.2446. Review.

10.

Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.

Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK.

J Am Geriatr Soc. 2014 Dec;62(12):2261-72. doi: 10.1111/jgs.13153. Review.

11.
12.

Reduction in the use of benzodiazepines and cyclopyrrolones in general practice.

Jørgensen VK, Toft BS.

Pharm Pract (Granada). 2008 Jul;6(3):136-41. Epub 2008 Sep 15.

13.

Retrospective population cohort study on hip fracture risk associated with zolpidem medication.

Lin FY, Chen PC, Liao CH, Hsieh YW, Sung FC.

Sleep. 2014 Apr 1;37(4):673-9. doi: 10.5665/sleep.3566.

14.

Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study.

Bakken MS, Engeland A, Engesæter LB, Ranhoff AH, Hunskaar S, Ruths S.

Eur J Clin Pharmacol. 2014 Jul;70(7):873-80. doi: 10.1007/s00228-014-1684-z. Epub 2014 May 9.

15.

Anxiety in Parkinson's disease: identification and management.

Chen JJ, Marsh L.

Ther Adv Neurol Disord. 2014 Jan;7(1):52-9. doi: 10.1177/1756285613495723. Review.

16.

Symptoms of anxiety or depression and risk of fracture in older people: the Hertfordshire Cohort Study.

Gale CR, Dennison EM, Edwards M, Sayer AA, Cooper C.

Arch Osteoporos. 2012;7:59-65. doi: 10.1007/s11657-012-0080-5. Epub 2012 Apr 12.

17.
18.

Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States.

Khong TP, de Vries F, Goldenberg JS, Klungel OH, Robinson NJ, Ibáñez L, Petri H.

Calcif Tissue Int. 2012 Jul;91(1):24-31. doi: 10.1007/s00223-012-9603-8. Epub 2012 May 8. Review.

19.

Ten-year trends in benzodiazepine use in the Dutch population.

Sonnenberg CM, Bierman EJ, Deeg DJ, Comijs HC, van Tilburg W, Beekman AT.

Soc Psychiatry Psychiatr Epidemiol. 2012 Feb;47(2):293-301. doi: 10.1007/s00127-011-0344-1. Epub 2011 Jan 23.

20.

Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.

Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck F.

Neuropsychopharmacology. 2011 Mar;36(4):848-56. doi: 10.1038/npp.2010.224. Epub 2010 Dec 8.

Supplemental Content

Support Center